Advertisement

MRI white matter hyperintensity in neuroleptic malignant syndrome (NMS)—a clue to pathogenesis?

  • T. Becker
  • J. Kornhuber
  • E. Hofmann
  • M. Weller
  • C. Rupprecht
  • H. Beckmann
Full Papers

Summary

The case of a young female patient with neuroleptic malignant syndrome (NMS) and extended MRI white matter hyperintensity in the left parietal and both occipital lobes is reported. MRI lesions resembled findings in hypertensive encephalopathy, they were not readily compatible with CNS vasculitis. Venous sinus thrombosis could be ruled out. Vascular encephalopathy with transient white matter edema and a small residual left parietal lesion is suggested. Neurochemical implications are discussed with particular reference to a possible involvement of excitatory amino acids in NMS pathogenesis.

Keywords

Neuroleptic malignant syndrome magnetic resonance imaging white matter pathology venous sinus thrombosis vasculitis dopamine excitatory amino acids glutamate 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Addonizio G, Susman VL, Roth SD (1987) Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiatry 22: 1004–1020Google Scholar
  2. Baca L, Martinelli L (1990) Neuroleptic malignant syndrome: a unique association with a tricyclic antidepressant. Neurology 40: 1797–1798Google Scholar
  3. Bunney WE, Garland BL (1983) Possible receptor effects of chronic lithium administration. Neuropharmacology 22: 367–372Google Scholar
  4. Buonanno FS, Moody DM, Ball MR, Wayne Laster D (1978) Computed cranial tomographic findings in cerebral sinovenous occlusion. J Comput Assist Tomogr 2: 281–290Google Scholar
  5. Coffey CE, Ross DR (1980) Treatment of lithium/neuroleptic neurotoxicity during lithium maintenance. Am J Psychiatry 137: 736–737Google Scholar
  6. Cohen WJ, Cohen NH (1974) Lithium carbonate, haloperidol, and irreversible brain damage. J Am Med Assoc 230: 1283–1287Google Scholar
  7. Coughlin WF, McMurdo SK, Reeves T (1989) MR imaging of postpartum cortical blindness. J Comput Assist Tomogr 13: 572–576Google Scholar
  8. Davis JM, Sakkas P, Hua J (1990) Remarks on neuroleptic malignant syndrome after a review of the first 500 cases. In: Stefanis CN, Rabavilas AD, Soldatos CR (eds) Psychiatry: a world perspective, vol 3. Excerpta Medica, Amsterdam New York Oxford, pp 262–267Google Scholar
  9. Ford LM, Sanberg PR, Norman AB, Fogelson MH (1989) MK-801 prevents hippocampal neurodegeneration in neonatal hypoxic-ischemic rats. Arch Neurol 46: 1090–1096Google Scholar
  10. de Groen PC, Aksamit AJ, Rakela J, Forbes GS, Krom RAF (1987) Central nervous system toxicity after liver transplantation. The role of cyclosporine and cholesterol. N Engl J Med 317: 861–866Google Scholar
  11. Greenan TJ, Grossman RI, Goldberg HI (1992) Cerebral vasculitis: MR imaging and angiographic correlation. Radiology 182: 65–72Google Scholar
  12. Halman M, Goldbloom DS (1990) Fluoxetine and neuroleptic malignant syndrome. Biol Psychiatry 28: 518–521Google Scholar
  13. Hauser RA, Lacey M, Knight R (1988) Hypertensive encephalopathy. Magnetic resonance imaging demonstration of reversible cortical and white matter lesions. Arch Neurol 45: 1078–1083Google Scholar
  14. Horn E, Lach B, Lapierre Y, Hrdina P (1988) Hypothalamic pathology in the neuroleptic malignant syndrome. Am J Psychiatry 145: 617–620Google Scholar
  15. Jones EM, Dawson A (1989) Neuroleptic malignant syndrome: a case report with postmortem brain and muscle pathology. J Neurol Neurosurg Psychiatry 52: 1006–1009Google Scholar
  16. Keck PE, Pope HG, Cohen BM, McElroy SL, Nierenberg AA (1989) Risk factors for neuroleptic malignant syndrome. Arch Gen Psychiatry 46: 914–918Google Scholar
  17. Kochhar A, Zivin JA, Lyden PD, Mazzarella V (1988) Glutamate antagonist therapy reduces neurologic deficits produced by focal central nervous system ischemia. Arch Neurol 45: 148–153Google Scholar
  18. Kwong YL, Yu YL, Lam KSL, Woo E, Ma JTC, Huang CY (1987) CT appearance in hypertensive encephalopathy. Neuroradiology 29: 215Google Scholar
  19. Lee S, Merriam A, Kim TS, Liebling M, Dickson DW, Moore GRW (1989) Cerebellar degeneration in neuroleptic malignant syndrome: neuropathologic findings and review of the literature concerning heat-related nervous system injury. J Neurol Neurosurg Psychiatry 52: 387–391Google Scholar
  20. Lewis LK, Hinshaw DB, Will AD, Hasso AN, Thompson JR (1988) CT and angiographic correlation of severe neurological disease in toxemia of pregnancy. Neuroradiology 30: 59–64Google Scholar
  21. Miller DD, Sharafuddin MJA, Kathol RG (1991) A case of clozapine-induced neuroleptic malignant syndrome. J Clin Psychiatry 52: 99–101Google Scholar
  22. Moore PM, Fauci AS (1981) Neurologic manifestations of systemic vasculitis. A retrospective and prospective study of the clinicopathologic features and responses to therapy in 25 patients. Am J Med 71: 517–524Google Scholar
  23. Müller T, Becker T, Fritze J (1988) Neuroleptic malignant syndrome after clozapine plus carbamazepine. Lancet ii: 1500Google Scholar
  24. Olney JW (1991) Excitotoxicity and neuropsychiatric disorders. In: Ascher P, Choi DW, Christen Y (eds) Glutamate, cell death and memory. Springer, Berlin Heidelberg New York Tokyo, pp 77–101Google Scholar
  25. Rail DL, Perkin GD (1980) Computerized tomographic appearance of hypertensive encephalopathy. Arch Neurol 37: 310–311Google Scholar
  26. Richards A, Graham D, Bullock R (1988) Clinicopathological study of neurological complications due to hypertensive disorders of pregnancy. J Neurol Neurosurg Psychiatry 51: 416–421Google Scholar
  27. Sawada H, Udaka F, Seriu N, Shindou K, Kameyama M, Tsujimura M (1990) MRI demonstration of cortical laminar necrosis and delayed white matter injury in anoxic encephalopathy. Neuroradiology 32: 319–321Google Scholar
  28. Shalev A, Munitz H (1986) The neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatr Scand 73: 337–347Google Scholar
  29. Simpson DM, Davis GC (1984) Case report on neuroleptic malignant syndrome associated with withdrawal from amantadine. Am J Psychiatry 141: 796–797Google Scholar
  30. Truwit CL, Denaro CP, Lake JR, DeMarco T (1991) MR imaging of reversible cyclosporin A-induced neurotoxicity. Am J Neuroradiology 12: 651–659Google Scholar
  31. Vandenplas O, Dive A, Dooms G, Mahieu P (1990) Magnetic resonance evaluation of severe neurological disorders in eclampsia. Neuroradiology 32: 47–49Google Scholar
  32. Weller M, Kornhuber J (1992 a) NMDA antagonists, schizophrenia, and neuroleptic malignant syndrome (letter). Arch Neurol (in press)Google Scholar
  33. Weller M, Kornhuber J (1992 b) A rationale for NMDA receptor antagonist therapy of the neuroleptic malignant syndrome. Med Hypothesis (in press)Google Scholar
  34. Zivin JA, Mazzarella V (1991) Tissue plasminogen activator plus glutamate antagonist improves outcome after embolic stroke. Arch Neurol 48: 1235–1238Google Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • T. Becker
    • 1
  • J. Kornhuber
    • 1
  • E. Hofmann
    • 2
  • M. Weller
    • 1
  • C. Rupprecht
    • 1
  • H. Beckmann
    • 1
  1. 1.Department of PsychiatryUniversity of WürzburgFederal Republic of Germany
  2. 2.Department of NeuroradiologyUniversity of WürzburgFederal Republic of Germany

Personalised recommendations